CN103012382A - 一种奥美沙坦酯的制备方法 - Google Patents
一种奥美沙坦酯的制备方法 Download PDFInfo
- Publication number
- CN103012382A CN103012382A CN2012105440742A CN201210544074A CN103012382A CN 103012382 A CN103012382 A CN 103012382A CN 2012105440742 A CN2012105440742 A CN 2012105440742A CN 201210544074 A CN201210544074 A CN 201210544074A CN 103012382 A CN103012382 A CN 103012382A
- Authority
- CN
- China
- Prior art keywords
- compound
- dimethylacetamide
- polyoxyethylene glycol
- glycol
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title abstract description 9
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 title abstract description 5
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 title abstract description 4
- 229960001199 olmesartan medoxomil Drugs 0.000 title abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- 229940125782 compound 2 Drugs 0.000 claims abstract description 10
- 229940125904 compound 1 Drugs 0.000 claims abstract description 9
- 239000003054 catalyst Substances 0.000 claims abstract description 7
- 239000002131 composite material Substances 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims abstract description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 24
- 239000005480 Olmesartan Substances 0.000 claims description 20
- 229960005117 olmesartan Drugs 0.000 claims description 20
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- -1 polyoxyethylene Polymers 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 11
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 11
- 229940125898 compound 5 Drugs 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 229940126214 compound 3 Drugs 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- CPVSCJMMEYRVOC-UHFFFAOYSA-N ClCC1=C(C=C(C(=O)O)C=C1C)C(=O)O Chemical compound ClCC1=C(C=C(C(=O)O)C=C1C)C(=O)O CPVSCJMMEYRVOC-UHFFFAOYSA-N 0.000 claims description 3
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 3
- 235000009518 sodium iodide Nutrition 0.000 claims description 3
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims description 2
- 229960003511 macrogol Drugs 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 229940057847 polyethylene glycol 600 Drugs 0.000 claims description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 3
- 239000003513 alkali Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 239000012535 impurity Substances 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940055053 benicar Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210544074.2A CN103012382B (zh) | 2012-12-05 | 2012-12-05 | 一种奥美沙坦酯的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210544074.2A CN103012382B (zh) | 2012-12-05 | 2012-12-05 | 一种奥美沙坦酯的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103012382A true CN103012382A (zh) | 2013-04-03 |
CN103012382B CN103012382B (zh) | 2016-10-05 |
Family
ID=47961536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210544074.2A Active CN103012382B (zh) | 2012-12-05 | 2012-12-05 | 一种奥美沙坦酯的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103012382B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103435602A (zh) * | 2013-07-31 | 2013-12-11 | 山东省医学科学院药物研究所 | 一种奥美沙坦酯的制备方法 |
CN103724333A (zh) * | 2013-12-26 | 2014-04-16 | 南通康鑫药业有限公司 | 一种奥美沙坦酯的合成方法 |
CN104592213A (zh) * | 2014-12-15 | 2015-05-06 | 山东新华制药股份有限公司 | 奥美沙坦酯中间体的制备方法 |
CN108341804A (zh) * | 2017-12-19 | 2018-07-31 | 嘉实(湖南)医药科技有限公司 | 高纯度奥美沙坦酯的制备方法 |
CN110452228A (zh) * | 2019-09-05 | 2019-11-15 | 黄冈鲁班药业股份有限公司 | 高纯度三苯基奥美沙坦乙酯的制备方法 |
CN107311990B (zh) * | 2017-07-25 | 2021-09-03 | 浙江华海致诚药业有限公司 | 一种奥美沙坦酯的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1045770C (zh) * | 1991-02-21 | 1999-10-20 | 三共株式会社 | 制备1-联苯甲基咪唑衍生物的方法 |
WO2005021535A2 (en) * | 2003-08-27 | 2005-03-10 | Zentiva, A.S. | A method of removing the triphenylmethane protecting group |
WO2007048361A1 (en) * | 2005-10-27 | 2007-05-03 | Zentiva, A.S. | A method of removing the triphenylmethane protecting group from precursors of antihypertensive drugs |
WO2007148344A2 (en) * | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Process for the preparation of olmesartan medoxomil |
TW201217363A (en) * | 2010-10-29 | 2012-05-01 | Interquim Sa | Process for obtaining olmesartan medoxomil |
-
2012
- 2012-12-05 CN CN201210544074.2A patent/CN103012382B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1045770C (zh) * | 1991-02-21 | 1999-10-20 | 三共株式会社 | 制备1-联苯甲基咪唑衍生物的方法 |
WO2005021535A2 (en) * | 2003-08-27 | 2005-03-10 | Zentiva, A.S. | A method of removing the triphenylmethane protecting group |
WO2007048361A1 (en) * | 2005-10-27 | 2007-05-03 | Zentiva, A.S. | A method of removing the triphenylmethane protecting group from precursors of antihypertensive drugs |
WO2007148344A2 (en) * | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Process for the preparation of olmesartan medoxomil |
TW201217363A (en) * | 2010-10-29 | 2012-05-01 | Interquim Sa | Process for obtaining olmesartan medoxomil |
Non-Patent Citations (1)
Title |
---|
吴泰志等: "抗高血压药奥美沙坦酯合成新路线和相关杂质的研究", 《药学学报》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103435602A (zh) * | 2013-07-31 | 2013-12-11 | 山东省医学科学院药物研究所 | 一种奥美沙坦酯的制备方法 |
CN103724333A (zh) * | 2013-12-26 | 2014-04-16 | 南通康鑫药业有限公司 | 一种奥美沙坦酯的合成方法 |
CN103724333B (zh) * | 2013-12-26 | 2016-06-08 | 南通康鑫药业有限公司 | 一种奥美沙坦酯的合成方法 |
CN104592213A (zh) * | 2014-12-15 | 2015-05-06 | 山东新华制药股份有限公司 | 奥美沙坦酯中间体的制备方法 |
CN107311990B (zh) * | 2017-07-25 | 2021-09-03 | 浙江华海致诚药业有限公司 | 一种奥美沙坦酯的制备方法 |
CN108341804A (zh) * | 2017-12-19 | 2018-07-31 | 嘉实(湖南)医药科技有限公司 | 高纯度奥美沙坦酯的制备方法 |
CN110452228A (zh) * | 2019-09-05 | 2019-11-15 | 黄冈鲁班药业股份有限公司 | 高纯度三苯基奥美沙坦乙酯的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103012382B (zh) | 2016-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103012382A (zh) | 一种奥美沙坦酯的制备方法 | |
CN102516130A (zh) | 一种盐酸二甲双胍的制备方法 | |
CN108017583A (zh) | 一种可博美的制备方法 | |
CN103360425A (zh) | 替诺福韦酯及其富马酸盐的合成方法 | |
CN104774196B (zh) | 一种苯并咪唑衍生物的制备方法 | |
CN104418807A (zh) | 一种2-乙氧基-1-[[2`-(羟基脒基)-联苯基]-4-基]甲基-1h-苯并咪唑-7-羧酸及其酯衍生物的制备方法 | |
CN104402946A (zh) | 卡格列净中间体及其无定形的制备方法 | |
CN103819450B (zh) | 一种苯甲酸阿格列汀的新制备方法 | |
CN1915990B (zh) | 一种制备洛沙坦的方法 | |
CN102731605B (zh) | 一种醋酸阿比特龙的纯化方法 | |
CN103664922A (zh) | 新晶型阿齐沙坦及其制备方法 | |
CN103435602A (zh) | 一种奥美沙坦酯的制备方法 | |
CN113233975A (zh) | 一种贝派地酸的制备方法 | |
CN103242286A (zh) | 一种双环醇药物组合物及其制备方法 | |
CN104744390A (zh) | 一种依折麦布中间体酮的制备方法 | |
CN102351849B (zh) | 一种奥美沙坦酯的制备方法 | |
CN111285876A (zh) | 利格列汀中间体异构体杂质、其制备方法和用途 | |
CN107540656B (zh) | 一种苯甲酸阿格列汀的制备方法 | |
CN104817482B (zh) | 2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用 | |
CN102206185B (zh) | 一种苄达赖氨酸及其类似物的精制工艺 | |
CN102050775B (zh) | 阿那曲唑杂质α,α,α′,α′-四甲基-5-(丁二酰亚胺-1-基甲基)-1,3-苯二乙腈及其制备方法 | |
CN104557943A (zh) | 一种维格列汀杂质的制备方法 | |
CN103304543A (zh) | 一种坎地沙坦酯的制备方法 | |
CN104230909B (zh) | 一种阿齐沙坦的制备方法 | |
CN107311989A (zh) | 一种奥美沙坦酯及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: DISHA PHARMACEUTICAL INDUSTRY GROUP CORP., LTD. Free format text: FORMER OWNER: WEIHAI DIZHIYA PHARMACHEM. DEVELOPMENT CO., LTD. Effective date: 20150908 Free format text: FORMER OWNER: DISHA PHARMACEUTICAL INDUSTRY GROUP CORP., LTD. DISHA PHARMACEUTICAL GROUP SHANDONG DISHA PHARMACEUTICAL CO., LTD. Effective date: 20150908 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150908 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205 Shandong city of Weihai province by the district Gushan Town Applicant before: WEIHAI DIZHIYA PHARMACHEM DEV Co.,Ltd. Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Shandong Disha Pharmaceutical Co.,Ltd., Disha Phamaceutical Group |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Fuli Inventor after: Zhang Zhaoxing Inventor after: Zhang Hongqiang Inventor after: Qin Litai Inventor after: Li Wei Inventor after: Li Zongwen Inventor after: Xia Haijian Inventor before: Zhang Zhaoxing Inventor before: Zhang Hongqiang Inventor before: Qin Litai Inventor before: Li Wei Inventor before: Li Zongwen Inventor before: Xia Haijian |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171129 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Co-patentee after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200520 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Co-patentee after: Dijia Pharmaceutical Group Co.,Ltd. Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Co-patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210608 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP02 | Change in the address of a patent holder |
Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP03 | Change of name, title or address |
Address after: No. 268, Tianrun Road, Wendeng Economic and Technological Development Zone, Weihai City, Shandong Province, 264200 Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
CP03 | Change of name, title or address |